Research programme: mesenchymal stem cells therapeutics - Mesoblast

Drug Profile

Research programme: mesenchymal stem cells therapeutics - Mesoblast

Alternative Names: Fucosylated mesenchymal lineage adult stem cells; Fucosylated MLCs

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mesoblast
  • Class Stem cell therapies
  • Mechanism of Action Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 17 Mar 2016 Mesoblast in-licenses ex vivo fucosylation technology from Harvard Medical School
  • 17 Mar 2016 Mesoblast has patent protection for the licensed ex vivo fucosylation technology in USA
  • 17 Mar 2016 Preclinical trials in Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top